Menopause HRT and depression: identify the mood question first

Menopausal hormone therapy can be discussed when menopausal symptoms and mood concerns occur together, but it is not an FDA-approved treatment for major depressive disorder. A randomized study found fewer new depressive-symptom episodes with a studied estradiol-plus-progesterone regimen among initially well participants in the menopause transition; that prevention finding does not show how to treat someone with established depression. The useful first step is to name the mood problem, its timing and the intended treatment goal.¹²³

“Depression” in a search query may mean transient low mood, a cluster of symptoms during a transition, a diagnosed major depressive episode, or a recurrence of a long-standing disorder. The same word cannot be used as the endpoint for all of them. A clinic claiming to “fix menopause depression” should specify which condition it means and how it is assessed.

Three different starting points

This distinction is practical, not semantic. A person with night sweats and interrupted sleep may feel low and benefit from a discussion about the sleep and vasomotor symptoms. Another person may have a mood disorder that needs its own assessment and care. Both concerns can deserve attention at the same visit, but neither should be inferred solely from age or hormone levels.

The night-sweat and sleep article separates symptom-linked awakening from another sleep problem. A mood discussion needs a similar separation: what is directly observed, what is diagnosed, and what is only a proposed mechanism?

What the prevention trial measured

The 2018 randomized trial studied transdermal estradiol with intermittent micronized progesterone versus placebo over 12 months among initially euthymic perimenopausal and early postmenopausal women. It measured the onset of clinically significant depressive symptoms on a research scale. Fewer participants assigned to the hormone regimen crossed that scale threshold at least once than participants assigned to placebo.¹

That is a meaningful study of prevention of symptoms in a selected group. It is not an FDA indication, a general recommendation that all perimenopausal women should use HRT, or a trial of treating current major depression. The effect also varied by menopausal stage in the paper; it should not be converted into a guarantee for every age or formulation.

The authors’ specific regimen matters. A custom-compounded pellet package, another patch, or testosterone treatment cannot borrow its result because “hormones” is not a single intervention. Neither can a clinic cite a symptom-score difference as proof that a person will avoid a future depressive disorder.

Professional guidance asks for an integrated assessment

Guidelines for perimenopausal depression emphasize that reproductive stage can be relevant while mood symptoms still require a proper psychiatric and medical assessment. They distinguish established depression treatment from hormone treatment of coexisting menopausal symptoms. A symptom that arises during perimenopause is not automatically caused by estrogen fluctuation, and a previous depression history does not make menopause irrelevant.²

The exact product label is another boundary. The cited estradiol transdermal system has named menopause-related uses and safety information; major depressive disorder is not one of its FDA-approved indications. Off-label clinical consideration is possible in medicine, but marketing should not label the use “FDA approved for depression.”³

Ask a provider who invokes “evidence-based HRT for depression” to point to the population and endpoint in the study. A current symptom, prevention of a future symptom score, and treatment of diagnosed depression each need different evidence and a different follow-up owner.

What a coordinated plan should document

Describe the mood changes in ordinary terms, when they began, whether hot flashes or sleep changed at the same time, and any prior mental-health diagnosis or treatment. Include current medicines and what has helped or worsened the symptoms. This record supports a clinician’s assessment; it is not a home diagnostic scale.

If both menopause and mental-health clinicians are involved, ask who will monitor which outcome. A hormone prescriber can explain a proposed product and menopause symptom goal. The clinician managing a mood disorder should know about any new hormone exposure and remain responsible for that disorder’s treatment plan. Neither team should assume the other has a complete medication list.

Ask:

• Is the proposed hormone product intended for a labeled menopausal symptom or an off-label mood claim?
• Which mood outcome is being followed: subjective distress, a symptom scale, or an established disorder?
• What would prompt a separate mental-health evaluation or a change in the coordinated plan?
• Which clinician will communicate the next decision?

At a hormone-therapy consultation, these questions keep the conversation helpful and accurate. The goal is to address the person’s actual symptoms and diagnoses with named evidence, rather than turning a promising prevention study into a universal depression treatment.